News: william pao

Next Page »

Photo: Lung Cancer Partnership

Friday, September 28th, 2012

Caroline Nebhan, right, a fourth-year student in the M.D./Ph.D. training program, explains a cancer research experiment to advocates from the National Lung Cancer Partnership who toured Vanderbilt-Ingram Cancer Center during their recent meeting in Nashville. Nebhan, who works in the research laboratory of William Pao, M.D., Ph.D., is studying the effects of a specific cancer […]

HER2 May Impact Lung Cancer Therapy

Friday, September 21st, 2012

Overcoming therapeutic resistance that inevitably develops is one of the major challenges in treating lung cancer. Non-small cell lung cancers that harbor mutations in the epidermal growth factor receptor (EGFR) are initially responsive to targeted therapies known as EGFR tyrosine kinase inhibitors (TKIs). However, most patients eventually develop resistance to these therapies. One such targeted […]

Uncommon BRAF Melanoma Mutation

Wednesday, July 18th, 2012

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation. The new study by co-first-authors Kimberly Brown Dahlman, Ph.D., Junfeng Xia, Ph.D., and Katherine Hutchinson, B.S., Vanderbilt-Ingram Cancer Center […]

Pathology Powerhouse

Wednesday, June 13th, 2012

From left, Kelly Boyd, DVM, Ph.D., James Crowe Jr., M.D., William Pao, M.D., Ph.D., Mary Zutter, M.D., and Yu Shyr, Ph.D., share a laugh at last week’s grand opening of the Translational Pathology Shared Resource (TPSR) laboratory in Medical Center North. The TPSR is Vanderbilt’s “pathology powerhouse” and is designed to translate basic science discoveries […]

Personalized Cancer Care Highlighted

Thursday, April 26th, 2012

A recent explosion in technological advances has created a new field known as translational “omics” that allows the measurement of molecules within a tissue or cell — genomics investigates DNA and proteomics examines proteins. These new omics-based tests may be used to guide patient therapy in the future. Such omics-based tests are much more complex […]

VUSM to Host IOM Meeting

Friday, April 20th, 2012

The Institute of Medicine of the National Academies (IOM), in conjunction with Vanderbilt University School of Medicine, will hold a regional meeting Monday, April 23, 4–6 p.m. in 208 Light Hall. The presentation, “Potential and Pitfalls of Gene and Omics-Based Treatment for Cancer,” will highlight recent advances in cancer research based on gene sequencing, along […]

My Cancer Genome Wins Technology Award

Friday, January 13th, 2012

Vanderbilt-Ingram Cancer Center physician-scientists who created the new online medical decision support tool called “My Cancer Genome” have been named winners of a $20,000 health care technology award sponsored by the National Cancer Institute. The contest, “Using Public Data for Cancer Prevention and Control: From Innovation to Impact Developer Challenge,” was presented as part of […]

Cohen’s Nobel-Winning Work Stands Test of Time

Thursday, December 8th, 2011

Twenty-five years ago on Dec. 10, King Carl XVI Gustaf of Sweden presented the Nobel Prize to Vanderbilt biochemist Stanley Cohen, Ph.D., for his discovery and characterization of epidermal growth factor (EGF) and its receptor. At the time, the implications of Cohen’s discovery two decades earlier had barely begun to be realized. Today the EGF […]

My Health Chat to Focus on Cancer

Thursday, December 8th, 2011

For decades, cancers have been treated based on how they look under a microscope. Now, researchers know that specific abnormalities in the DNA of tumor cells can make each person’s cancer respond differently to treatment — knowledge that offers an exciting new avenue for tailored therapy. Personalizing cancer treatment for an individual patient based on […]

Personalized Medicine for Lung Cancer

Monday, November 28th, 2011

Dr. William Pao, director of hematology and oncology at Vanderbilt-Ingram Cancer Center, explains what personalized cancer medicine means for the future of lung cancer treatment. Learn more about Personalized Cancer Medicine.